Updated jab in response to Omicron variant could be ready in 100 days: Pfizer CEO

Published On 2021-12-03 11:06 GMT | Update On 2021-12-03 11:06 GMT

New Delhi: Pfizer is working on an updated jab in response to the Omicron variant that could be ready in 100 days, according to the head of American multinational pharmaceutical giant, who said that people may need to have annual Covid-19 vaccinations for many years to come.

Pfizer's chief executive Dr Albert Bourla told the BBC that he is of the view that annual vaccinations would be needed to maintain a "very high level of protection" against the deadly disease that has claimed over five million lives across the world.

Bourla was speaking to the BBC before the emergence of the Omicron variant, first identified in South Africa and also before the announcement that the UK government had signed contracts to buy the 54 million additional Pfizer-BioNTech and 60 million Moderna doses for 2022 and 2023.

These deals include access to modified vaccines if needed to combat Omicron and future variants of concern, the Department of Health has said.

Dr Bourla said Pfizer had already made updated vaccines in response to the Beta, also first identified in South Africa, and Delta, first identified in India, variants but that they had not been needed.

The company is now working on an updated jab in response to the Omicron variant that could be ready in 100 days, the report added.

He said vaccines had helped save millions of lives during the pandemic, and without them, the "fundamental structure of our society would be threatened".

By the end of the year, Pfizer expects to have supplied three billion doses of its messenger ribonucleic-acid (mRNA) vaccine with four billion planned for next year.

There had been a global race to protect people, Dr Bourla said, but in 2022, countries would have "as many doses as they need".

Having to be stored at -70C, the Pfizer vaccine has been tricky to deploy in countries with limited health services.

But within a month or so, Pfizer says it will roll out a new formulation of the vaccine that can be stored for three months in a fridge, which Dr Bourla said, would make a "huge difference" for sub-Saharan African countries.

He also talked about vaccine hesitancy.

"For those that are just afraid, the only emotion of human beings stronger than fear is love," he said.

"So I am always using this argument that the decision to get another vaccine is not going to influence only your health, it is going to affect the health of others and particularly the health of the people you love the most because they are the ones that you will interact with.

"So take the courage to overcome your fears and do the right thing."

The total tally of COVID-19 cases and deaths globally now stands at 263,565,559 and 5,225,667 respectively. Total vaccine doses administered globally are 8,041,107,778, according to Johns Hopkins University.

Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Updated jab in response to Omicron variant could be ready in 100 days: Pfizer CEO

Similar News

Zydus Secures CDSCO Panel Go-Ahead For Phase III Trial of Empagliflozin-Metoprolol FDC

Reckitt names Karandeep Singh Duggal as new Region Head-Central India

Cipla inks pacts to invest in iCaltech Innovations

Dr Reddy's Labs gets USFDA EIR for New York facility

Sanofi to expand respiratory vaccines pipeline with acquisition of Vicebio

JnJ seeks USFDA approval for Icotrokinra to treat plaque psoriasis in adults, adolescents

Bayer Nubeqa gets EU nod in third indication for advanced prostate cancer

1-Year Ban for Fake Docs, Mandatory Disposal of Near-Expiry Stock: CDSCO Revises Pharma Export Rules